Business Wire

CA-PROSIMO

12.6.2024 16:01:30 CEST | Business Wire | Press release

Share
Prosimo and Palo Alto Networks bring Zero Trust to Application Workloads in Multi Cloud Environments

Prosimo, a leader in multi cloud networking software [MCNS], today announced an integration with Palo Alto Networks for a powerful new approach to security that protects applications and workloads in multi cloud environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612713674/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hop by Hop Traceability Including the Packets Being Actioned Within a Firewall (Graphic: Business Wire)

With Prosimo’s Full Stack Cloud Transit platform, customers can seamlessly integrate with Palo Alto Networks VM-Series Virtual Next-Generation Firewall (NGFW), allowing enterprises to deploy security as close as possible to the workloads they protect. This architecture greatly reduces the time and effort required to secure application access across multi cloud environments for users and workloads.

“Together with Palo Alto Networks VM-Series virtual firewalls, we’re providing organizations with a Zero Trust framework so they can be confident their application workloads are secure while ensuring fast and reliable connectivity to and across cloud providers,” said Prosimo Vice President of Product Mani Ganesan. “This integration allows enterprises to improve observability, increase operational efficiency, and safely gives them more control of their cloud environment.”

Join the Office Hours to explore the use case and see a live demo here.

Most integrations today focus on orchestrating firewalls and inserting them in the path of cloud network traffic, where they rely on IP addresses/port numbers to redirect traffic. Prosimo instead provides service insertion policies that allow users to define sophisticated rules that determine which traffic will be routed for advanced inspection to the firewall.

Prosimo simplifies deployment for two flexible architectures for Palo Alto Networks VM-Series virtual firewalls:

  • Centralized: VM-Series virtual firewall is deployed into a centralized VPC for east-west (VPC-to-VPC) or north-south (Internet egress and ingress, cloud to on-premises) traffic. This is the most common Prosimo model and provides security control and ongoing manageability.
  • Distributed: VM-Series virtual firewalls are deployed in each virtual private cloud. This method is typically used in cases where VPCs need to be isolated and require local ingress or egress.

“Speed is critical in the cloud, so the speed of operations in configuring software firewalls, like the VM-Series virtual firewall, needs to match the speed of cloud deployments,” said Vitaliy Sivetskiy, senior product manager of Palo Alto Networks. “Integrating Prosimo’s Full Stack Cloud Transit and Palo Alto Networks VM-Series virtual firewall makes network security teams' lives easier. Our single intuitive operating model for connectivity and virtual firewall insertion means customers have more time to focus on application business innovation versus managing network and security infrastructure. This enables organizations to help protect all clouds, the right way, with agility.”

Link to Solution Brief

Providing Multi-Layer Security to Navigate Cloud Firewall Complexity

While a well-constructed multi cloud networking architecture can enhance security, scaling of firewalls can be complex. Common challenges include ensuring the virtual firewall can handle the required elasticity associated with growing cloud resources, managing complex network configurations for auto scaling, and implementing ongoing route updates to direct traffic through the next-generation firewall while maintaining segmentation and isolation.

Integrating Prosimo with Palo Alto Networks VM-Series virtual firewalls ensures enhanced security and scalability across the network and application layer. Palo Alto Networks Next-Generation Firewalls offer comprehensive Layer 7 inspection, while Prosimo stands out as a leading provider in the MCNS market capable of delivering network segmentation spanning Layer 3 to Layer 7.

With native integration, customers can provision new virtual firewalls in a few clicks. From a single dashboard, users can manage the lifecycle of those firewalls, quickly scaling up or down while segmenting the necessary subnets and corresponding cloud-native elements.

Customers can see immediate benefits from the integration through:

  • Migrating to Palo Alto Networks software next-generation firewalls faster, eliminating blind spots for both network and security teams.
  • Right-sizing software firewalls to optimize cloud costs.
  • Using the existing firewall investment to segment east-west and north-south data movement within clouds.

Go to prosimo.io to learn how Prosimo and Palo Alto Networks enable enterprises to build, modernize, and future-proof cloud infrastructure.

About Prosimo

Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have successfully adopted Prosimo to roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612713674/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye